- Raymond James set a $287 price target for Ascendis Pharma A/S, suggesting an 8.33% potential increase despite a downgrade to “Outperform.”
- Ascendis Pharma A/S regained full rights to its TransCon technology for metabolic diseases, including obesity, from Novo Nordisk, enhancing control and future revenue potential.
- The company authorized a $400 million share repurchase program and reported positive clinical trial data for its TransCon CNP treatment, boosting investor confidence.
On September 15, 2026, Raymond James set a $287 price target for Ascendis Pharma A/S (NASDAQ: ASND), a biopharmaceutical company that develops therapies using its TransCon technology. Despite downgrading Ascendis Pharma A/S to an “Outperform” rating, the target suggests an 8.33% potential increase from its trading price of $264.92 at the time of the announcement.
This rating follows Ascendis Pharma A/S’s announcement that it will regain full rights to its TransCon technology for metabolic diseases from its former partner, Novo Nordisk. This strategic move gives Ascendis Pharma A/S complete control over developing and selling products in this area, including for obesity, without any ongoing financial obligations to its former partner.
Further supporting the company’s investment outlook, the Board of Directors authorized a $400 million share repurchase program. A share repurchase is when a company buys back its own stock from the open market. This action can signal management’s confidence in the company’s future and often increases the value of the remaining shares.
Positive clinical trial data also contributes to the company’s valuation. As highlighted by GlobeNewswire, recent results for its TransCon CNP treatment showed it stabilized a dangerous skull condition in infants with achondroplasia. The treatment also demonstrated linear growth benefits, with an improvement of 0.42 in a key growth measurement over 52 weeks.
